Journal of Thrombosis and Thrombolysis

Papers
(The TQCC of Journal of Thrombosis and Thrombolysis is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection55
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team42
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry33
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series27
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding24
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison23
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients23
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum16
Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies15
Metformin therapy in COVID-19: inhibition of NETosis14
Forensic autopsy-confirmed thrombosis-related deaths: the danger in the bones13
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis12
Popliteal cysts are not a risk factor for lower extremity deep vein thrombosis12
Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction11
Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism11
SARS-CoV-2 antibody research in patients with unprovoked pulmonary embolism in COVID-19 pandemic period11
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study11
0.40599393844604